Galderma Group AG Logo

Galderma Group AG

A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.

GALD | SW

Overview

Corporate Details

ISIN(s):
CH1335392721
LEI:
89450001OK6O8ELQ4584
Country:
Switzerland
Address:
Zählerweg 10, 6300 Zug
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Galderma Group AG is a pure-play pharmaceutical company specializing in dermatology. It operates across the full spectrum of skin health through three main business units: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. The company develops and markets an innovative, science-based portfolio of premium brands and treatments designed to meet the individual needs of both consumers and patients. Galderma is focused on providing solutions for a wide range of dermatological conditions, positioning itself as a leader solely dedicated to advancing skin health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Galderma Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Galderma Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-31 N/A Non-Executive member Sell None 935,664.75 CHF
2025-03-28 N/A Non-Executive member Sell None 1,876,958.07 CHF
2025-03-27 N/A Non-Executive member Sell None 265,440.84 CHF
2025-03-26 N/A Non-Executive member Sell None 673,175.70 CHF
2025-03-25 N/A Executive member Buy None 243,205.38 CHF
2025-03-20 N/A Non-Executive member Sell None 1,156,106.24 CHF
2025-03-20 N/A Non-Executive member Sell None 47,702.12 CHF
2025-03-17 N/A Executive member Sell None 7,962,599.99 CHF
2024-12-20 N/A Non-Executive member Sell None 105,831.00 CHF
2024-11-06 N/A Non-Executive member Sell None 177,500.00 CHF

Peer Companies

Company Country Ticker View
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan 4886
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan 4503

Talk to a Data Expert

Have a question? We'll get back to you promptly.